Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 24.7 SEK -1.2% Market Closed
Market Cap: 857.3m SEK

Relative Value

The Relative Value of one ORX stock under the Base Case scenario is 35.49 SEK. Compared to the current market price of 24.7 SEK, Orexo AB is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORX Relative Value
Base Case
35.49 SEK
Undervaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
28
vs Industry
72
Median 3Y
0.9
Median 5Y
1.1
Industry
2.6
Forward
1.6
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.2
Industry
21.7
Forward
-8.7
vs History
9
vs Industry
Median 3Y
-3.8
Median 5Y
-3.8
Industry
16.6
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-3.7
Industry
22.5
vs History
vs Industry
7
Median 3Y
2.9
Median 5Y
2.7
Industry
2.3
vs History
4
vs Industry
61
Median 3Y
1.3
Median 5Y
1.4
Industry
2.9
Forward
2.3
vs History
4
vs Industry
74
Median 3Y
1.6
Median 5Y
1.7
Industry
5.5
vs History
4
vs Industry
25
Median 3Y
20.2
Median 5Y
-5
Industry
13.1
Forward
-326.1
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-6.5
Industry
16.6
Forward
-25.6
vs History
15
vs Industry
Median 3Y
-4.9
Median 5Y
-4.8
Industry
15.8
vs History
9
vs Industry
Median 3Y
-4.8
Median 5Y
-4.5
Industry
19.1
vs History
4
vs Industry
34
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

ORX Competitors Multiples
Orexo AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Orexo AB
STO:ORX
852.3m SEK 1.6 -4.2 83.1 -8.4
US
Eli Lilly and Co
NYSE:LLY
939.9B USD 15.8 51 34.3 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.5B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
252.8B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 4.8 29.9 108.2 158.3
CH
Novartis AG
SIX:NOVN
206B CHF 4.6 17.7 11.3 14.5
US
Merck & Co Inc
NYSE:MRK
239.1B USD 3.7 12.6 9 10.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 8.9 10.4
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
SE
Orexo AB
STO:ORX
Average P/E: 23.1
Negative Multiple: -4.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.6
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 405.2
83.1
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
34.3
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 1 878.3
Negative Multiple: -8.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
1%
10.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3